Compare UBCP & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBCP | IMMX |
|---|---|---|
| Founded | 1902 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.4M | 82.6M |
| IPO Year | N/A | 2021 |
| Metric | UBCP | IMMX |
|---|---|---|
| Price | $14.16 | $6.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 7.0K | ★ 1.3M |
| Earning Date | 11-06-2025 | 11-07-2025 |
| Dividend Yield | ★ 6.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $30,516,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | $10.58 | ★ N/A |
| Revenue Growth | ★ 4.40 | N/A |
| 52 Week Low | $12.25 | $1.34 |
| 52 Week High | $15.64 | $7.73 |
| Indicator | UBCP | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 63.45 | 66.71 |
| Support Level | $13.21 | $4.50 |
| Resistance Level | $14.30 | $7.73 |
| Average True Range (ATR) | 0.37 | 0.68 |
| MACD | 0.07 | 0.20 |
| Stochastic Oscillator | 74.16 | 65.44 |
United Bancorp Inc operates as a bank holding company that provides commercial and retail banking services. Through its subsidiary (Unified Bank), the company provides a broad range of banking and financial services, which includes accepting demand, savings, and time deposits and granting commercial, real estate, and consumer loans. It serves customers in Belmont, Harrison, Jefferson, Tuscarawas, Carroll, Athens, Hocking, and Fairfield counties and the surrounding localities. The bank also operates in Marshall County West Virginia.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.